Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results

被引：0
|
作者：
Schuster, S. J.
Neelapu, S. S.
Gause, B. L.
Muggia, F. M.
Gockerman, J. P.
Sotomayor, E. M.
Winter, J. N.
Flowers, C. R.
Stergiou, A. M.
Kwak, L. W.
机构：
[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[2] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] NCI, Bethesda, MD 20892 USA
[4] NYU, Med Ctr, New York, NY 10016 USA
[5] Duke Univ, Med Ctr, Durham, NC USA
[6] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[7] Northwestern Univ, Chicago, IL 60611 USA
[8] Emory Univ, Atlanta, GA 30322 USA
[9] Biovest Int, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results
    Schuster, S. J.
    Neelapu, S. S.
    Gause, B. L.
    Muggia, F. M.
    Gockerman, J. P.
    Sotomayor, E. M.
    Winter, J. N.
    Flowers, C. R.
    Stergiou, A. M.
    Kwak, L. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] BiovaxID vaccine therapy of follicular lymphoma in first remission: Phase III blinded safety update
    Stergiou, Angelos M.
    Neelapu, Sattva S.
    Casciano, Roman
    Jaffee, Margo A.
    Kwak, Larry W.
    BLOOD, 2007, 110 (11) : 197B - 197B
  • [3] BiovaxID® could prolong remission duration in follicular lymphoma patients in Phase III clinical trial
    不详
    EXPERT REVIEW OF VACCINES, 2009, 8 (07) : 828 - 828
  • [4] BiovaxID® could prolong remission duration in follicular lymphoma patients in Phase III clinical trial
    不详
    IMMUNOTHERAPY, 2009, 1 (04) : 522 - 522
  • [5] Biovaxid vaccine therapy of follicular lymphoma in first remission: Long-term follow-up of a phase II trial and status of a controlled, randomized phase III trial
    Gause, B. L.
    Cohen, C. M.
    Katz, L. M.
    Watson, T. M.
    Arikian, S.
    Stergiou, A. M.
    EXPERIMENTAL HEMATOLOGY, 2006, 34 (09) : 54 - 54
  • [6] BiovaxID™ vaccine therapy of follicular lymphoma in first remission:: Long-term follow-up of a phase II trial and status of a controlled, randomized phase III trial.
    Santos, C
    Stern, L
    Katz, L
    Watson, T
    Barry, G
    BLOOD, 2005, 106 (11) : 686A - 686A
  • [7] High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial
    Horning, SJ
    Negrin, RS
    Hoppe, RT
    Rosenberg, SA
    Chao, NJ
    Long, GD
    Brown, BW
    Blume, KG
    BLOOD, 2001, 97 (02) : 404 - 409
  • [8] Results of a clinical trial of idiotype specific vaccine therapy for B cell lymphoma.
    Hsu, FJ
    Caspar, CB
    Kwak, LW
    Liles, T
    Czerwinski, D
    Taidi, B
    Levy, R
    BLOOD, 1995, 86 (10) : 1079 - 1079
  • [9] Idiotype vaccine therapy of follicular lymphoma in first remission: Association of t(14;18) and disease free survival in a phase II cohort.
    Gause, B. L.
    Neelapu, S. S.
    Cohen, C. M.
    Katz, L. M.
    Watson, T.
    Stergiou, A. M.
    Kwak, L. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 442S - 442S
  • [10] Vaccine therapy of follicular lymphoma in first remission: Long-term follow-up of phase II results and high rate of chemotherapy-induced complete remissions in a controlled, randomized phase III trial.
    Neelapu, SS
    Gause, BL
    Nikcevich, DA
    Schuster, SJ
    Winter, J
    Gockerman, JP
    Sotomayor, E
    Inghirami, G
    Muggia, F
    Watson, T
    Snow, S
    Kubovic, P
    Ferraro, M
    Jaffe, ES
    Reynolds, CW
    Kwak, LW
    BLOOD, 2003, 102 (11) : 307B - 308B
12345